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ABSTRACT 
Burn patients frequently require autograft harvesting to facilitate wound healing, often 
resulting in significant pain. Liposomal bupivacaine is indicated for administration into a 
surgical site to produce postsurgical analgesia. The objective of this study was to evaluate 
efficacy, safety, and duration of postoperative analgesia with liposomal bupivacaine for 
donor site pain in burn patients. This was an observational, case–control study including 
adult patients with <20% total body surface area (TBSA) burned who received liposomal 
bupivacaine for postoperative pain management after autograft harvesting from lower 
extremity donor site(s). Patients from the case group were matched to historical control 
patients treated with traditional pain management. The primary outcome was the 
cumulative pain scores on postoperative day one measured by the area under the curve 
(AUC0–24). Secondary outcomes included AUC0–72, total milligram morphine 
equivalents (MME), length of stay, and adverse events. Data were collected in 36 patients 
who received liposomal bupivacaine, with 21 patients eligible for matching to historical 
controls. Patients included in the intervention and control groups were well-matched at 
baseline. Patients in the intervention group had a significantly lower median (IQR) AUC0–
24 [578 (408,740) vs. 680 (544,803); p = 0.05] and shorter length of stay [4 days (1,9.5) 
vs. 6 days (318); p = 0.01]. No differences in adverse events related to the administration 
of liposomal bupivacaine or opioid-related adverse events were observed. Results 
indicate liposomal bupivacaine is safe and effective in burn patients. The results of this 
study add to the limited body of literature examining efficacy in this population. 
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1. INTRODUCTION 
 
 
Post-operative pain can be a significant issue for patients and caregivers. In fact, pain 
has been found to be one of the three most common causes of delayed discharge after 
ambulatory surgery. A study from 2003 found that approximately 80% of patients stated 
they experienced acute pain after surgery, despite being on pain management therapy. 
Post-operative pain can be associated with several negative outcomes such as 
tachycardia, hypertension, myocardial ischemia, decreased alveolar ventilation, and poor 
wound healing [1]. 
Current guideline recommendations are consistent in recommending a multimodal pain 
management approach, including non-opioid management whenever possible to reduce 
the risk of opioid-related adverse events [[2], [3], [4]].The frequency of opioid-related 
adverse events is relatively common, with a published incidence ranging from 20% to 
48%. These can include nausea/vomiting, constipation, confusion/agitation, drug 
dependence, respiratory depression, and itching/hives. These events can be problematic 
for patients and are associated with a significant clinical impact such as an increased 
length of hospital stay, increased hospital costs, and ultimately inadequate pain control 
[5]. 
Recently, opioid-related morbidity and mortality has reached epidemic levels in the United 
States. In 2015, there were over 33,000 deaths attributed to opioid overdose in the United 
States, an increase of nearly 5000 compared with the previous year. For the first time, 
drug overdose has surpassed firearms and motor vehicle trauma as the most common 
cause of accidental death among adults. The epidemic appears to have been fueled by 
the prescription of opioids. More stringent laws have been passed in some states in which 
prescribers are obligated to prescribe no more than seven days of opioids for a first 
prescription [6]. 
Liposomal bupivacaine is indicated by the FDA for administration into a surgical site to 
produce postsurgical analgesia. It utilizes a drug-delivery mechanism which allows 
bupivacaine to release slowly for up to 72 h. This unique formulation of bupivacaine 
contains a DepoFoam® technology that is composed of naturally occurring biodegradable 
and biocompatible lipids that are cleared by normal metabolic pathways. The dosage form 
encapsulates bupivacaine in a multivesicular liposomal drug delivery technology that 
 
 
releases bupivacaine over time as lipid membranes reorganize. After bupivacaine has 
been released and is absorbed systemically, the distribution, metabolism, and excretion 
is expected to be the same as for any bupivacaine HCl solution formulation [7]. Liposomal 
bupivacaine has been shown to reduce opioid consumption post-operatively and improve 
patient outcomes in a variety of surgical procedures, including plastic surgery [[8], [9], 
[10], [11], [12], [13], [14]]. Its use in burn surgery patients has been extremely limited, to 
our knowledge. Case reports describing its use have been limited by small sample sizes 
and lacked clinical outcomes data due to not utilizing a control group for comparative 
efficacy [15,16]. Furthermore, these reports did not describe the use of a standardized 
institution-specific protocol. The objective of this study was to evaluate the efficacy, 
safety, and duration of post-operative analgesia with liposomal bupivacaine versus 
traditional management strategies of donor site pain in burn surgery patients utilizing a 
standardized protocol. 
2. METHODS 
2.1. PROTOCOL CREATION 
This study was conducted at a 315-bed safety-net, academic medical center. The study 
institution is a Level I Trauma Center and American Burn Association (ABA) — verified 
Regional Burn Center with 15 inpatient beds within the Burn Center. In order to maximize 
patient safety with the use of liposomal bupivacaine, an institution-specific protocol for 
burn surgery patients was developed and implemented prior to study initiation. The 
protocol described the steps of the medication use process, including the indications for 
use, preparation, administration, and monitoring parameters for patients who received 
liposomal bupivacaine based on information provided in the package insert. Liposomal 
bupivacaine is currently available as a 266 mg/20 mL vial with a maximum dose of one 
vial per surgical site. It may then be diluted with 280 mL of Lactated Ringer’s or 0.9% 
sodium chloride. A total of 30 mL of 0.5% or 60 mL of 0.25% bupivacaine HCl may also 
be added based on surgeon preference. The solution is instilled via a 25-gauge needle 
or tumescence cannula no sooner than 20 min after the administration of other local 
anesthetics. Formulations of bupivacaine other than liposomal bupivacaine should not be 
administered within 96 h following initial administration. The protocol also outlined routine 
 
 
monitoring of vital signs and pain scores during the procedure and after the use of 
liposomal bupivacaine. One-on-one nursing and OR staff education emphasizing 
potential adverse events with the use of liposomal bupivacaine (e.g. nausea, vomiting, 
and neurological and cardiovascular adverse events) was conducted in real time for each 
patient [7]. 
2.2. STUDY DESIGN 
This was a prospective, observational, case–control study approved by the local 
Institutional Review Board. After protocol implementation, data were collected 
prospectively in patients who received liposomal bupivacaine beginning on October 1, 
2016 through January 6, 2018 and retrospectively in historical controls managed with 
traditional pain management strategies from January 1, 2015 through September 30, 
2016. Patients were included who were at least 18 years of age, admitted to the Burn 
Center, had <20% total body surface area (TBSA) burned, and received an autograft 
utilizing a lower extremity donor site. Patients who were pregnant, incarcerated, had a 
history of opioid abuse, or who had chronic opioid use prior to admission were excluded 
from the analysis. Historical controls were matched based on age (±10 years), %TBSA 
(±5%), donor site size (±100 cm2) and depth of injury (superficial, partial, and/or full 
thickness). 
2.3. DATA COLLECTION 
Data collected from the electronic medical record included age, gender, race, weight, 
%TBSA, length of stay, serum creatinine on the date of procedure, depth of injury 
(superficial, partial, full thickness), size and location of donor site, dose of liposomal 
bupivacaine, amount and type of diluent utilized, other local anesthetics utilized, and 
administration technique. Pain scores were collected at 30 min and two hours post-
operatively, and every four hours through 72 h post-procedure. Morphine milligram 
equivalents (MME) used over 24 and 72 h postoperatively were also assessed. Safety 
endpoints included opioid-induced (nausea/vomiting, constipation, pruritus, urinary 
retention), cardiovascular (bradycardia, hypotension, arrhythmias), and neurologic 
(respiratory depression, weakness, paresthesia, paralysis, local anesthetic systemic 
toxicity requiring lipid rescue) adverse effects. 
 
 
2.4. OUTCOMES 
The primary outcome was area under the pain score time curve on postoperative day one 
(AUC0–24). In the event of a missing pain score, one of three methods was utilized as 
described in a similar study by Dasta, et al. [7]. If the missing pain score was prior to the 
first non-missing pain score, the median score from other patients at the same time point 
was utilized. If the missing pain score was between two non-missing pain scores, linear 
interpolation was utilized. Finally, if the missing pain score was after the last non-missing 
pain score, the last observed pain score was carried forward. 
Secondary endpoints assessed efficacy and safety. Efficacy outcomes included a 
composite endpoint of pain scores up to 72 h post-operatively measured by the AUC0–
72, total MME opioid rescue medications on postoperative day one and postoperative 
days one through three, and the amount of liposomal bupivacaine instilled per cm2 of 
donor site (area-normalized dose). Safety outcomes included adverse events (opioid-
related, cardiovascular, and neurologic) and incidence of local anesthetic systemic 
toxicity requiring lipid rescue. 
2.5. STATISTICAL ANALYSIS 
Statistical tests were performed using Minitab® 16 statistical software (Minitab Inc., State 
College, PA). Normally distributed data were reported with mean (SD), whereas non-
parametric data were reported with median [interquartile range (IQR)]. Normality was 
tested using the Anderson–Darling Normality Test. The Student’s paired t-test was used 
to detect differences between normally distributed, continuous data. For non-parametric, 
continuous data, a Wilcoxon Signed Rank test was used to detect potential differences. 
The Fisher’s Exact or χ2 tests were used to detect differences in nominal data. The 
significance level (alpha) was predetermined to be less than or equal to 0.05. A sample 
size calculation was not performed a priori as a convenience sample of all eligible patients 
who received liposomal bupivacaine was utilized. 
3. RESULTS 
3.1. PATIENTS 
 
 
A total of 41 patients received liposomal bupivacaine, 36 of which met inclusion criteria. 
Reasons for exclusion were history of chronic opioid use (n = 2), incarcerated (n = 1), and 
use of liposomal bupivacaine outside the institution-specific protocol (n = 2). Data were 
collected in all 36 patients who received liposomal bupivacaine (overall cohort). Of these 
patients, 21 had pain scores charted through at least 24 h postoperatively (intervention 
group) and were eligible to be matched to historical controls (control group). 
Patient demographics are listed in Table 1. The included patients were middle-aged, 
white males with a small %TBSA. The overall cohort, intervention group, and control 
group were well-matched for age, gender, race, mechanism of injury (thermal vs. non-
thermal), burn injury depth (superficial, partial, and/or full thickness), weight, serum 
creatinine on the day of surgery, and size of donor site with no statistically significant 
differences seen between groups. The only difference between the intervention group 
and the control group was that the intervention group had a significantly smaller median 
(IQR) %TBSA when compared to the control group [4% (2,7) vs. 5% (4,9); p = 0.04]. 
However, the overall difference in %TBSA was not regarded to be clinically significant by 
the authors and would have no effect on the overall management of these patients. 
Details regarding the dosing of liposomal bupivacaine in both the overall cohort and 
intervention group are listed in Table 2, including total dose, size of donor site, area-
normalized dose of liposomal bupivacaine, and use of a diluent. Of note, no patients 
received additional bupivacaine and all patients received lidocaine prior to the 
administration of liposomal bupivacaine. 
 
 
 
Table 1. Patient demographics. 
Parameter 
Overall cohort 
(n = 36) 
Intervention group 
(n = 21) 
Control group 
(n = 21) 
p-
value 
Age, years (mean ± SD) 46 ± 17 45 ± 16 44 ± 18 0.42 
Male, n (%) 22 (61) 18 (86) 14 (67) 0.28 
 
 
Parameter 
Overall cohort 
(n = 36) 
Intervention group 
(n = 21) 
Control group 
(n = 21) 
p-
value 
Caucasian, n (%) 24 (67) 19 (90) 17 (81) 0.66 
Thermal injury, n (%) 31 (86) 19 (90) 18 (86) 1.00 
%TBSA [median (IQR)] 
3 (2,5) 
n = 31 
4 (2,7) 
n = 16 
5 (4,9) 
n = 16 
0.04 
Superficial thickness, n (%) 1 (3) 1 (5) 1 (5) 1.00 
Partial thickness, n (%) 27 (75) 15 (71) 15 (71) 1.00 
Full thickness, n (%) 9 (25) 4 (19) 4 (19) 1.00 
Weight, kg [median (IQR)] 
81.6 (69.1,101) 
n = 35 
81.6 (68,105.5) 72.6 (67.1,91.8) 0.53 
SCr, mg/dL (mean ± SD) 
0.85 ± 0.22 
n = 30 
0.87 ± 0.23 
n = 19 
0.77 ± 0.13 
n = 19 
0.07 
Size of donor site, 
cm2 [median (IQR)] 
200 (100,438) 300 (200,650) 300 (200,700) 0. 
 
Table 2. Liposomal bupivacaine dosing. 
Parameter 
Overall cohort 
(n = 36) 
Intervention group 
(n = 21) 
Dose of liposomal bupivacaine, mg [median (IQR)] 151 (72,266) 266 (106,266) 
Size of donor site, cm2 [median (IQR)] 200 (100,438) 300 (200,650) 
Area-normalized dose of liposomal bupivacaine, 
mg/cm2 [median (IQR)] 
0.50 (0.32,1.22) 0.38 (0.25,1.11) 
Use of diluted liposomal bupivacaine, n (%) 27 (75) 16 (76) 
Amount of diluent used, mL [median (IQR)] 280 (8280) 280 (15,280) 
 
3.2. PRIMARY OUTCOME: AUC0–24 
 
 
Fig. 1 displays results for AUC0–24 in the intervention and control groups. The median 
(IQR) AUC0–24 in the liposomal bupivacaine group was 577.5 (407.9,739.8) versus 
680.3 (543.6,802.8) in the historical control group and this difference was found to be 
statistically significant (p = 0.05). 
 
Fig. 1. Primary Outcome: AUC0–24 of matched intervention patients who received 
liposomal bupivacaine vs. AUC0–24 of historical control patients. 
3.3. SECONDARY OUTCOMES 
Secondary outcomes are reported in Table 3. In regard to the efficacy endpoints, there 
were no statistically significant differences in AUC0–72 or total MME administered over 
the first 24 or 72 h postoperatively. There was, however, significant decrease in median 
(IQR) hospital length of stay when comparing the intervention group vs. the control group 
[4 days (1,9.5) vs. 6 days (318); p = 0.01]. In regard to safety endpoints, significantly more 
patients had nausea/vomiting in the control group (95% vs. 67%; p = 0.05), and there 
were no statistically significant differences found in days to first bowel movement, 
documented pruritus, documented urinary retention, episodes of bradycardia or 
hypotension, or rates of arrhythmias. A bowel regimen was prescribed in greater than 
95% of patients in both groups. No patients in either group experienced serious adverse 
events such as cardiac arrest, persistent anesthesia, paresthesia, weakness, paralysis, 
 
 
respiratory depression requiring administration of naloxone, or local anesthetic toxicity 
requiring lipid rescue. 
Table 3. Secondary outcomes. 
Outcome 
Intervention group 
(n = 21) 
Control group 
(n = 21) 
p-value 
AUC0-72 [median (IQR)] 
3914 (34,824,984) 
n = 8 
3138 (22,765,814) 
n = 8 
1.00 
Total MME over hours 0–24 [median (IQR)] 88.5 (33,110.5) 97.5 (63,137.3) 0.10 
Total MME over hours 0–72 [median (IQR)] 
246.3 (93,312.4) 
n = 8 
137 (75,518) 
n = 8 
0.62 
Length of stay, days [median (IQR)] 4 (1,9.5) 6 (318) 0.01 
Documented N/V, n (%) 14 (67) 20 (95) 0.05 
Days to first bowel movement [median (IQR)] 
1 (1,1.5) 
n = 9 
2 (1,2.5) 
n = 9 
0.10 
Documented pruritus, n (%) 3 (14) 4 (19) 1.00 
Documented urinary retention, n (%) 1 (5) 1 (5) 1.00 
Episodes of bradycardia [median (IQR)] 0 (0,0) 0 (0,0) 0.68 
Episodes of hypotension [median (IQR)] 0 (0,0) 0 (0,0) 1.00 
Any arrhythmia, n (%) 0 (0) 1 (5) 1.00 
MME = milligram morphine equivalents; N/V = nausea/vomiting. 
4. DISCUSSION 
Data from a study conducted by Apseloff, et al. showed time to onset of analgesia with 
liposomal bupivacaine and bupivacaine HCl to be similar. This was a Phase I, 
randomized, sequential-cohort, crossover study including 132 healthy volunteers 
randomized to four sequential cohorts to receive subcutaneous normal saline in one arm 
and either liposome bupivacaine 40 mg or bupivacaine HCl 7.5 mg in the other. At 30, 15, 
five, and two minutes after study drug administration for cohorts one through four 
 
 
respectively, an incision was made in each arm and 18% acetic acid solution was applied 
to elicit pain. The primary outcome was a subject’s assessment in pain intensity on a 
100 mm visual analog scale. At two minutes post-dose, mean (SD) pain intensity scores 
were 26% lower with liposome bupivacaine versus placebo [47 (23) vs. 61 (19); 
p < 0.0001]. A greater than 30% reduction in mean pain scores was also observed for 
both liposome bupivacaine and bupivacaine HCl compared with saline placebo at five, 
15, and 30 min after study drug administration, which was significant versus placebo at 
all three time points (p < 0.0001) [8,9]. 
Previously published studies have described the use of liposomal bupivacaine in a variety 
of non-burn surgical procedures [[9], [10], [11], [12], [13], [14]]. A meta-analysis by Dasta, 
et al. evaluated the comparative efficacy of liposomal bupivacaine versus bupivacaine 
HCl for post-surgical analgesia in over 900 patients. The analysis included nine double-
blind, placebo, or active-controlled studies which evaluated the use of liposomal 
bupivacaine versus bupivacaine HCl, bupivacaine HCl plus epinephrine, or placebo. 
Surgical procedures included inguinal hernia repair, total knee arthroplasty, 
hemorrhoidectomy, breast augmentation, and bunionectomy. The results demonstrated 
patients who received liposomal bupivacaine had a significantly lower mean cumulative 
pain score (AUC) over 72 h post-operatively than patients who did not receive liposomal 
bupivacaine (283 vs. 329, respectively; p = 0.039). Additionally, patients who received 
liposomal bupivacaine had significantly less mean MME (12.2 vs. 19.0; p < 0.001), had a 
longer median time to opioid use (9.9 h vs. 2.7 h; p < 0.001), and had less patients with 
>1 opioid-related adverse event [101 (20.1%) vs. 147 (35.9%); p < 0.001] than patients 
who did not receive liposomal bupivacaine [10]. 
Liposomal bupivacaine has also been studied in a variety of plastic surgery procedures, 
which is relevant as data is often extrapolated from this patient population to the burn 
surgery population when such data is lacking. A systematic review by Vyas, et al. 
evaluated five studies reviewing the use of liposomal bupivacaine in abdominal wall 
reconstruction, augmentation mammoplasty, and mastectomy procedures. Overall, these 
studies demonstrated patients who received liposomal bupivacaine had lower pain 
scores, decreased opioid consumption in the first 72 h post-operatively, and a decreased 
 
 
length of stay versus those who did not receive liposomal bupivacaine, similar to results 
described by Dasta, et al. [10,11]. 
Data are extremely limited describing the use of liposomal bupivacaine in burn surgery 
patients. Published data are limited to a case series from two institutions utilizing 
liposomal bupivacaine for donor site pain control in small burns (mean burn size 12% and 
7% TBSA in each cohort). Our patient population included patients with similar burn size, 
suggesting smaller burn sizes (i.e. <10% TBSA) are most likely to see a benefit from the 
use of liposomal bupivacaine. These cohorts included small sample sizes of 20 patients 
and 5 patients. Both utilized liposomal bupivacaine into the donor site to assist with post-
operative pain control, and found that pain scores appeared to be well-controlled with no 
donor site complications noted in either study [15]. While one cohort compared 
postsurgical medication use with the amount of opioids consumed the day before surgery, 
neither compared results to a control group to determine efficacy during the postoperative 
period. There was variation in these cohorts in the rates of addition of plain bupivacaine 
to the liposomal bupivacaine; however, in our study no patients received plain 
bupivacaine, which allowed us to control for this potential confounder. There was also an 
abstract presented at a recent American Burn Association meeting describing the use of 
liposomal bupivacaine for skin graft donor site analgesia. This abstract describes a 
retrospective review of 27 adult patients [median (IQR) burn size 4% (1–7)] who received 
full and split-thickness skin autografts utilizing liposomal bupivacaine for donor site pain 
management. Pain scores were reported postoperatively at 24 and 48 h and patients 
were asked to report pain from the donor site and the graft site separately. Results of this 
study include 90% of patients reported donor site pain as 3 or less 48 h after surgery and 
80% of patients stated donor site pain was less than graft site pain (although differences 
in the scores were not reported). One patient experienced a donor site infection which 
was treated successfully with antibiotics and all donor sites had re-epithelialized by 
postoperative day 14. However, this study did not mention the use of a control group 
comparing donor site pain scores specifically and using the graft site as a comparator 
group is likely subject to additional variability (e.g., size of wound) outside of the use of 
liposomal bupivacaine. Donor sites also varied and included anterior thigh, posterior and 
anterior torso, and left arm. Dosing techniques in relation to liposomal bupivacaine were 
 
 
not described in the abstract nor was there indication that a standardized protocol was 
utilized in terms of donor site location, medication administration techniques, or wound 
dressings. To our knowledge, this study has not been published to date [16]. Overall, 
these studies in burn surgery patients included small sample sizes limited to descriptive 
analyses, did not use control groups to determine efficacy in relation to concomitant pain 
medications in the postoperative period, and lacked clinical outcomes data or use of 
standardized protocols. Our study addresses these gaps in the literature in this patient 
population. 
4.1. SUMMARY OF KEY FINDINGS 
In our study, there was a statistically significant difference in the AUC0–24 and hospital 
length of stay in patients who received liposomal bupivacaine versus those who did not. 
This demonstrates the potential for liposomal bupivacaine to be used as part of a multi-
modal pain management pathway for donor site pain in burn patients. Although FDA-
approved labeling states liposomal bupivacaine may produce postoperative analgesia for 
up to 72 h, the results from our study would indicate patients did not appear to see 
continued benefit past 24 h. This shorter duration of action was not surprising, as burn 
patients frequently require larger and more frequent dosing of medications due to the 
hypermetabolic state associated with burn injury. The onset and duration observed within 
our patient population are similar to those described in the study by Apseloff, et al. [8]. 
Additionally, the statistically significant difference found at AUC0–24 in combination with 
the decreased length of stay indicate patients were more likely to be discharged sooner 
in the intervention group, likely due to better post-operative pain control. In comparison 
to the meta-analysis conducted by Dasta, et al., our patients utilized significantly more 
opioids postoperatively than were used for other types of surgical procedures (which is to 
be expected in burn patients); however, they were still able to experience a statistically 
significant difference in pain control and length of stay [9]. While we did not observe a 
statistical difference in MME between groups, the difference in pain control and length of 
stay suggest these patients may be able to tolerate lower doses of opioid medications 
than traditionally utilized. In an effort to decrease overall opioid use, this practice could 
be addressed in the future through provider and nursing education. Finally, we saw a 
 
 
significantly higher incidence of nausea/vomiting in the control group vs. the intervention 
group. We also observed a trend towards longer time to first bowel movement, increased 
pruritus, and increase in arrhythmias in the control group vs. the intervention group, but 
these differences were not statistically significant nor were we powered to detect these 
differences. 
Our study reinforces the safety of the use of liposomal bupivacaine in this patient 
population as there were no major adverse effects noted. There appeared to be a trend 
of more opioid-related adverse effects in the control group, although we were not powered 
to detect this difference. To our knowledge, this is the largest study evaluating the use of 
liposomal bupivacaine in burn patients using a standardized protocol and the first to utilize 
a matched cohort for efficacy data evaluation. 
4.2. STRENGTHS AND LIMITATIONS 
Noted strengths of this study included its prospective study design using a matched 
cohort of patients using relevant factors, including standardization of using a lower 
extremity donor site in both groups and consistent wound dressings. We were able to 
describe a novel use of liposomal bupivacaine using a standardized protocol describing 
administration techniques to maximize patient safety, which can provide guidance for 
other Burn Centers nationally. Our study is the first of its kind, to our knowledge, to assess 
for efficacy and relevant clinical outcomes in this patient population using a matched 
cohort. Finally, we were able to use an opioid-sparing pain management strategy in burn 
patients during a national opioid crisis. 
The major limitation of our study included that this was a single–center study, although 
this was a convenience sample which includes more patients than previous abstracts in 
burn surgery patients. The interpatient variability in the reporting of pain scores may have 
affected the results; however, this would be true for both groups. There were potentially 
charting inconsistencies between the historical controls and intervention groups as the 
health system utilized two different electronic health records during the study periods; 
however, methods described by Dasta, et al. were utilized to account for and standardize 
these differences. We did not collect data on the use of other non-opioid pain 
 
 
management strategies such as acetaminophen, non-steroidal anti-inflammatory 
medications, or gabapentin due to the lack of ability to quantify the amount of these 
medications between the two groups, which is consistent with previous studies examining 
the use of liposomal bupivacaine. 
Finally, we did not conduct a full economic analysis as part of this study, as this was 
beyond our scope. If the efficacy of liposomal bupivacaine in burn patients is supported 
by additional studies, economic analyses will be warranted, including evaluation of cost 
savings from decreased length of hospital stay versus cost of liposomal bupivacaine 
administration. Based on current average cost of inpatient hospital stay for our burn unit, 
which includes wound care and nursing time, each day costs approximately $13,146, 
whereas one vial of liposomal bupivacaine costs $315. Based on an estimated savings 
of $26,292 from two fewer days admitted to the burn unit, and accounting for the expense 
of receiving one dose of liposomal bupivacaine, this translates into a potential overall cost 
savings of more than $25,000 per patient. 
5. CONCLUSIONS 
Results from this study indicate liposomal bupivacaine is a safe, effective, and economical 
non-opioid pain management option for treating donor site pain for 24 h in smaller TBSA 
(<20%) burn patients after autograft harvesting. The patients in our study who received 
liposomal bupivacaine vs. traditional pain management strategies had statistically lower 
pain scores demonstrated by AUC0–24 and a significantly shorter length of hospital stay. 
Our protocol describing appropriate use of liposomal bupivacaine can be shared with 
other Burn Centers nationally with the potential for a multi-site study. 
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